We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 91.00 | 1.20 | 1.60 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/3/2023 11:00 | 20220516 RNS explains conversion principle and NASDAQ listing.A good place to start. | bibs | |
18/3/2023 17:18 | Hi why is just a big price difference between Nasdaq and LSE share price 2.75 v/s 1.55? | spkp313703 | |
17/3/2023 07:49 | OKYO on NASDAQ opened over 90 percent up on placement price, on appreciation of trial news yesterday. Closed 14 percent up on very high volume. Great prospects ahead ? | bibs | |
16/3/2023 15:46 | Huge volume being traded over on NASDAQ - they understand and like the RNS(s). | faraweigh2 | |
16/3/2023 11:22 | OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. "We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. | bibs | |
16/3/2023 10:56 | Market Capitalisation is a small fraction of where it will be in time.Funding sorted and set for real growth in due course.DYOR | faraweigh2 | |
16/3/2023 08:16 | Funding in place and trials underway. Good to go! | faraweigh2 | |
16/3/2023 07:28 | 1.9p placing huh. Whoosh. | terminator101 | |
15/3/2023 10:39 | Life changing positive potential here for those with sufficient skin in the game.Sit back and watch it unfold ; ) | faraweigh2 | |
14/3/2023 15:51 | Bibs did you take any profit off the table at 8p to BUY at under 3p or were you greedy too?. :0) | p5tvr | |
14/3/2023 15:26 | Won't Buy these at under 2.5p for much longer: " offerings utilized the full amount of the Company’s UK ordinary shares available for sale at this time " | bibs | |
14/3/2023 14:55 | Reread the thread bell end.Some understand what's happening here and some don't have a clue.You sit amongst the latter lol! | faraweigh2 | |
14/3/2023 12:21 | Management and investors well placed now for future gains.Funding in place for significant growth. | faraweigh2 | |
14/3/2023 12:02 | Yes . 2023 is going to be a big year for them . like every year since they assembled this pile of excrement. | kasspass | |
14/3/2023 11:12 | lol absolutely clueless ; ) | faraweigh2 | |
14/3/2023 08:59 | Oh dear!! Hands up those who wished that they now sold into the spike to 8p? That's what you get for being too GREEDY. LOL :0) | p5tvr | |
13/3/2023 15:49 | Okyo CEO states:"2023 is going to be a big year for us!"Shareholder value to be added here... | bibs | |
04/3/2023 12:10 | Hearing IIs accumulating here ahead of significant, global exposure to DE treatment markets.Trade patterns and volumes appear to back this up.DYOR | faraweigh2 | |
02/3/2023 11:15 | Next rinse and repeat at 0.911p. You have been warned. Regards, F911 RMC | firestorm911 | |
01/3/2023 13:17 | Oops! LOL. :0) | p5tvr | |
28/2/2023 15:23 | So much for that rise to 8p! LOL :0) | p5tvr |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions